A case of refractory Sézary syndrome with large-cell transformation responsive to brentuximab vedotin.
نویسندگان
چکیده
Author Contributions:Drs Kirsner and Lamel had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Lamel, Vivas, Kirsner. Acquisition of data: Lamel, Richmond. Analysis and interpretation of data: Lamel, Richmond, Braun, Kirsner. Drafting of the manuscript: Lamel, Richmond. Critical revision of the manuscript for important intellectual content: Lamel, Richmond, Braun, Vivas, Kirsner. Administrative, technical, or material support: Richmond. Study supervision: Kirsner.
منابع مشابه
Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
IMPORTANCE The prognosis of advanced cutaneous T-cell lymphoma (CTCL), including Sézary syndrome and mycosis fungoides (MF), is poor. So far, no curative option apart from allogeneic stem cell transplantation is available. Large cell transformation often hallmarks cases with a more aggressive clinical course, and large tumor cells may express CD30. Recently, brentuximab vedotin, a conjugate of ...
متن کاملComplete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
TO THE EDITOR: [Abstract] The treatment outcome of relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma (ENKL) is poor. Brentuximab vedotin, an anti-CD30 antibody-drug conjugate, has recently been approved for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large-cell lymphoma (ALCL). We report on a case of a 63-year-old man who presented with multiple skin lesions,...
متن کاملBrentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome – a case report and discussion
Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.
متن کاملBrentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
Up to 40% of patients with advanced Hodgkin lymphoma (HL) become refractory or relapsed after current standard chemotherapy, among which primary refractory HL confers a particularly poor outcome. With intensive salvage chemotherapy and autologous stem cell transplantation, the long-term remission rate for these patients was only 30%, but more selective treatments with higher therapeutic index a...
متن کاملPrimary bone lymphoma with multifocal osteolytic lesions: a rare case report with review of literature
vedotin could be a viable treatment option for refractory CD30-positive ENKL without causing significant toxicity, even in heavily pretreated patients. However, since this case report is the first to show CR in CD30-positive ENKL with brentuximab vedotin, further studies will be required to confirm these results and establish a dosing schedule. This report implies that brentuximab vedotin could...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- JAMA dermatology
دوره 150 2 شماره
صفحات -
تاریخ انتشار 2014